Progestins

Aetna covers etonogestrel subdermal implant (Nexplanon) and medroxyprogesterone acetate IM 150 mg/mL (Depo‑Provera) for prevention of pregnancy; covers medroxyprogesterone for gender‑affirming therapy only if the member can make an informed decision, has a diagnosis of gender dysphoria, comorbidities are reasonably controlled, contraindications/side effects have been reviewed, and minors are managed by or in consultation with a transgender‑care specialist with mental health collaboration; it also covers Depo‑Provera 400 mg/mL as adjunctive/palliative therapy for inoperable/recurrent/metastatic endometrial or renal carcinoma and progesterone IM for amenorrhea or abnormal uterine bleeding due to hormonal imbalance when no organic pathology is present. Limitations: many plans exclude contraceptives so check benefit descriptions; all other indications for etonogestrel, medroxyprogesterone IM, and progesterone IM are considered experimental/investigational, and the Depo‑Provera 400 mg/mL formulation was discontinued on October 27, 2020.